Cargando…
Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
Autores principales: | Gonzalez-Rodriguez, Elena, Aubry-Rozier, Bérengère, Stoll, Delphine, Zaman, Khalil, Lamy, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385537/ https://www.ncbi.nlm.nih.gov/pubmed/32742916 http://dx.doi.org/10.1016/j.jbo.2020.100294 |
Ejemplares similares
Ejemplares similares
-
Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
por: Galvano, Antonio, et al.
Publicado: (2020) -
“Inflammaging” and bone in the OsteoLaus cohort
por: Fischer, Jessica, et al.
Publicado: (2020) -
Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2018) -
Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review
por: Camponovo, C., et al.
Publicado: (2020) -
Galvano-Therapeutics
Publicado: (1874)